Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts.

Lehman College and the Graduate Center, the City University of New York, Bronx, New York 10468-1589, USA.
AIDS patient care and STDs (Impact Factor: 3.58). 01/2009; 22(12):977-87. DOI: 10.1089/apc.2008.0048
Source: PubMed

ABSTRACT Abstract Survival among perinatally infected children and youth with HIV has been greatly extended since the advent of highly active antiretroviral therapies. Yet, adherence to HIV medication regimens is suboptimal and decreases as children reach adolescence. This paper reports on a qualitative study examining psychosocial factors associated with adherence among perinatally infected youth ages 10-16 years. The study was based on in-depth interviews with a sample of 30 caregivers participating in a comprehensive health care program in New York City serving families with HIV. A subsample comprising 14 caregivers of children ages 10 and above is the focus of this paper. The analysis identified a number of themes associated with the psychosocial context of managing adherence among older children. Maintaining adherence was an ongoing challenge and strategies evolved as children matured. Regimen fatigue and resistance to taking the medications were major challenges to maintaining adherence among the oldest children. In other cases, caregivers developed a kind of partnership with their child for administering the medications. Disclosure to the child of his or her HIV status was used as a strategy to promote adherence but seemed to be effective only under certain circumstances. Social support appeared to have an indirect influence on adherence, primarily by providing caregivers with temporary help when needed. Health care professionals were an important source of disclosure and adherence support for parents. The study illustrates the interplay of maturational issues with other contextual psychosocial factors as influences on adherence among older children and adolescents.

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Quantifying pediatric immunologic recovery by highly active antiretroviral therapy (HAART) initiation at different CD4 percentage (CD4%) and age thresholds may inform decisions about timing of treatment initiation. METHODS: HIV-1-infected, HAART-naive children in Europe and the Americas were followed from 2002 through 2009 in PENPACT-1. Data from 162 vertically infected children, with at least World Health Organization "mild" immunosuppression and CD4% <10th percentile, were analyzed for improvement to a normal CD4% (>= 10th percentile) within 4 years after HAART initiation. Data from 209 vertically infected children, regardless of immune status, were analyzed for CD4% outcomes at 4 years and viral failure within 4 years. RESULTS: Seventy-two percent of baseline immunosuppressed children recovered to normal within 4 years. Compared with "severe" immunosuppression, more children with "mild" immunosuppression (difference 36%, 95% confidence interval [CI]: 22% to 49%) or "advanced" immunosuppression (difference 20.8%, 95% CI: 5.8% to 35.9%) recovered a normal CD4%. For each 5-year increase in baseline age, the proportion of children achieving a normal CD4% declined by 19% (95% CI: 11% to 27%). Combining baseline CD4% and age effects resulted in >90% recovery when initiating HAART with "mild" immunosuppression at any age or "advanced" immunosuppression at age <3 years. Baseline CD4% effects became greater with increasing age (P = .02). At 4 years, most immunologic benefits were still significant but diminished. Viral failure was highest in infancy (56%) and adolescence (63%). CONCLUSIONS: Initiating HAART at higher CD4% and younger ages maximizes potential for immunologic recovery. Guidelines should weigh immunologic benefits against long-term risks.
    Pediatrics 09/2014; 134(4). DOI:10.1542/peds.2014-0527 · 5.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to study the impact of physical, psychological and socio-economic factors on the quality of life (QL) of HIV-infected children and their effect on antiretroviral therapy (cART) adherence. We carried out a multicentre pilot, cross-sectional research in a cohort of 71 HIV-infected children (HIV-group) from three Hospitals in Madrid (Spain) and 34 healthy children (non-HIV-group) from public schools of the same neighbourhood of this city. The children were between 5 and 14 years old. To determine the perceived QL, the Spanish version of the child health profile (CHIP-CE) questionnaire was used. The socio-environmental dimension of the QL was measured via semi-structured interviews. The indirect method of semi-structured family interview was used to study the cART adherence. The HIV-group did not show differences in comparison with the non-HIV-group when they had a high perception of their health status and wellbeing. However, the HIV-group showed a worse ‘emotional comfort’, a lower level in the ‘satisfaction with self’ and in the ‘concentration ability’, a lower evaluation of family relationships and was more prone to perform with threat to achievements and to perform ‘individual risk avoidance’ than non-HIV-group. This work showed that the impact of HIV infection in children extends to all aspects of the QL, including physical, psychological, socio-educational and family, being associated with worse clinical outcomes in HIV/AIDS and had a negative effect on cART adherence in children. Summing up, the HIV-group had a poor perception of the overall QL.
    Vulnerable Children and Youth Studies 02/2015; 10(2):163-177. DOI:10.1080/17450128.2015.1026866
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The perspectives and practices of health care workers (HCWs) regarding disclosure to HIV-infected children have not been adequately investigated ten years after the roll-out of pediatrics antiretroviral therapy (ART). The aim of the study was to examine the opinions of HCWs about disclosure to HIV-infected children and determine their role in disclosure to children accessing ART in health centers in South Africa. This was a cross-sectional survey using a semi-structured questionnaire among HCWs in ART centers at three hospitals and 48 primary health facilities in two provinces in South Africa. Of the 206 HCWs, 140 (68.2%) were nurses, 44 (21.5%) were lay counsellors, and 4 (2%) were doctors. The majority (n = 183, 89.3%) felt that disclosure benefits children and they should be told about their HIV status. Over half (n = 93, 51.4%) recommended 11-18 years as the appropriate age to disclose. Half (n = 99, 48.5%) said that caregivers should take the lead to disclose, 87 (42.7%) said that disclosure is a shared responsibility of caregivers and HCWs, and 18 (8.8%) said HCWs should lead disclosure. HCWs perceived their role as that of preparing the caregiver for disclosure and the child to understand the disease. However, the lack of guidelines and training on disclosure counselling for children affects their ability to fully participate in disclosure to children. There is a need to adopt the World Health Organizations' disclosure guidelines for children and adapt them to the local cultural and community contexts and train HCWs to guide, support, and assist caregivers in their disclosure to HIV-infected children.
    01/2015; 3:e893. DOI:10.7717/peerj.893